BIOMAT Database Logo BIOMAT Database Logo

[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. 1998

Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Department of Urology, Okayama University Medical School, Japan.

OBJECTIVE There is no effective therapy against hormone refractory prostate cancer. This led us to evaluate the effectiveness and toxicity of cis-platinum (CDDP) and ifosfamide (IFM) combination chemotherapy in the patients with hormone-unresponsive carcinoma of the prostate. METHODS Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1.2 g/m2/day intravenously on day 1 through day 5 of 28-day cycle. RESULTS Twenty seven patients with hormone unresponsive prostate cancer were enrolled onto this trial. Of these patients, seven (26%) demonstrated a partial objective response (PR), and ten (37%) a stable disease (ST). The response duration of PR cases lasted from 6 to 49 months with a median of 16 months and the response duration of PR + ST cases lasted from 3 to 36 months with a median of 10 months. Subjective improvement was obtained in 11 patients (41%). Survival duration of all cases were 4 to 89 months with a median of 23 months and probabilities of survival at 3 years and 5 years were 36% and 24%, respectively. The toxicity of this treatment was mostly mild to moderate, anemia (96%), leukocytopenia (89%), anorexia (81%), alopecia (67%), thrombocytopenia (44%), hematuria (38%), renal dysfunction (19%) and liver dysfunction (7%) were noticed. Severe toxicity was observed in two cases, one acute renal failure and one endotoxin shock. CONCLUSIONS We conclude that CDDP and IFM combination chemotherapy was active regimen for hormone unresponsive prostate cancer.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000505 Alopecia Absence of hair from areas where it is normally present. Alopecia, Androgenetic,Baldness,Male Pattern Baldness,Pseudopelade,Alopecia Cicatrisata,Alopecia, Male Pattern,Androgenetic Alopecia,Androgenic Alopecia,Baldness, Male Pattern,Female Pattern Baldness,Hair Loss,Pattern Baldness,Alopecia Cicatrisatas,Alopecia, Androgenic,Alopecias, Androgenic,Androgenic Alopecias,Baldness, Female Pattern,Baldness, Pattern,Hair Losses,Loss, Hair,Losses, Hair,Male Pattern Alopecia

Related Publications

Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.
February 2006, Acta medica Okayama,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
[Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer].
December 1991, Hinyokika kiyo. Acta urologica Japonica,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
cis-Platinum combination chemotherapy of bladder cancer: an update.
January 1979, Cancer clinical trials,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
[Combination chemotherapy with peplomycin, cis-platinum and mitomycin C in gynecologic cancer].
September 1985, Gan no rinsho. Japan journal of cancer clinics,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
[Combination chemotherapy with cis-platinum, vinblastine and adriamycin for non-small cell lung cancer].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.
November 2010, Experimental and therapeutic medicine,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.
January 2003, International journal of clinical pharmacology research,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.
January 1980, Journal of cancer research and clinical oncology,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
Treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide, adriamycin and cis-platinum.
September 1984, British journal of obstetrics and gynaecology,
Y Maki, and T Tsushima, and Y Nasu, and H Kumon, and H Ohmori, and T Tanahashi, and K Nanba, and T Ohashi, and K Kondo, and T Saika, and T Asahi, and M Saegusa, and Y Ozaki, and Y Yamashita, and Y Katayama, and M Kobuke, and S Uno, and J Ochi, and K Kobashi, and K Hata
[A trial of combination chemotherapy. Cis-platinum, peplomycin and adriamycin for advanced prostatic cancer].
August 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!